Ligand Pharmaceuticals

Valuation Analysis

About the Company

Ligand Pharmaceuticals en bref

Ligand Pharmaceuticals (LGND) is currently trading at 239,63 € with a market capitalization of 4,8 Md €. The trailing P/E ratio stands at 35.84x, with a forward P/E of 24.29x. The 52-week range spans from 95,89 € to 240,78 €; the current price is 0.5% below the yearly high. Year-over-year revenue growth stands at +14.1%. The net profit margin stands at 55.95%.

💰 Dividende

Ligand Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

10 analystes évaluent Ligand Pharmaceuticals (LGND) au consensus : None. L'objectif de cours moyen est de 242,00 €, soit un potentiel de +0.99% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 215,33 € à 287,68 €.

Ligand Pharmaceuticals : la thèse d'investissement en détail

Ligand Pharmaceuticals (LGND) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 14.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 83.16%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 55.95%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 35.61x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 24.29x is meaningfully below the trailing 35.84x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 99.2% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (9.79%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Ligand Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.